Atlas Trials

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Clinical trial NCT04649073 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04649073
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma (MM)
Start date
2021-02-18
Primary completion
2025-04-09
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.